Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases
- PMID: 18279055
- DOI: 10.1586/14737140.8.2.151
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases
Abstract
Osteosarcoma is the most common form of primary malignant bone tumor. The use of chemotherapy drugs with many side effects, including high-dose methotrexate, doxorubicin, cisplatin and ifosfamide, has greatly improved osteosarcoma survival compared with surgery alone. However, for 20 years, overall survival remained at a plateau of 60-70% in nonmetastatic disease and 20-30% in metastatic osteosarcoma owing to lung metastases. Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a new agent that improves overall osteosarcoma survival (chemotherapy without L-MTP-PE 70% versus with L-MTP-PE 78%; p = 0.03). L-MTP-PE offers additional benefit for osteosarcoma treatment in combination with chemotherapy, particularly ifosfamide-containing regimens. Clinical experience indicates that side effects such as fever are temporary and controlled or prevented with ibuprofen and/or acetoaminophen premedication; severe side effects are rare. Although surgery will remain the main approach for osteosarcoma treatment of lung metastases, L-MTP-PE combined with other modalities, including chemotherapy, appears to be of benefit in these patients as well.
Similar articles
-
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Hematol Oncol Clin North Am. 1995. PMID: 7490249 Review.
-
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.Future Oncol. 2006 Jun;2(3):333-43. doi: 10.2217/14796694.2.3.333. Future Oncol. 2006. PMID: 16787112 Review.
-
Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Adv Exp Med Biol. 2014. PMID: 24924182 Review.
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.Am J Clin Oncol. 1995 Apr;18(2):93-9. doi: 10.1097/00000421-199504000-00001. Am J Clin Oncol. 1995. PMID: 7900714 Clinical Trial.
-
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566. Cancer. 2009. PMID: 19637348 Free PMC article. Clinical Trial.
Cited by
-
Expression and significance of secreted protein acidic and rich in cysteine in human osteosarcoma.Oncol Lett. 2017 Nov;14(5):5491-5496. doi: 10.3892/ol.2017.6871. Epub 2017 Sep 1. Oncol Lett. 2017. PMID: 29142603 Free PMC article.
-
Progress in the chemotherapeutic treatment of osteosarcoma.Oncol Lett. 2018 Nov;16(5):6228-6237. doi: 10.3892/ol.2018.9434. Epub 2018 Sep 12. Oncol Lett. 2018. PMID: 30405759 Free PMC article. Review.
-
A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma.Medicina (Kaunas). 2021 Feb 5;57(2):141. doi: 10.3390/medicina57020141. Medicina (Kaunas). 2021. PMID: 33562455 Free PMC article. Review.
-
Potential of human γδ T cells for immunotherapy of osteosarcoma.Mol Biol Rep. 2013 Jan;40(1):427-37. doi: 10.1007/s11033-012-2077-y. Epub 2012 Oct 14. Mol Biol Rep. 2013. PMID: 23065272 Review.
-
Mifamurtide: a review of its use in the treatment of osteosarcoma.Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000. Paediatr Drugs. 2010. PMID: 20481644 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
